CD6 and neoplasm: Interestingly, the transcriptomic signature of the KLRF1high NK-like ILC population correlated significantly with a better progression-free survival (PFS) and recurrence-free survival in the TCGA cohort whereas the signature of CD6+ ILC1s did not predict survival in any cohort (Figure S4C;Figure 5D), indicating a potential role for the KLRF1high NK-like ILC population in anti-tumor immunity.